You are currently browsing the tag archive for the ‘prevention’ tag.

Starting on 29 May 2013 with many Oral Sessions fresh updates on Stroke Large clinical trials (RCTs)
at 11:25-12:30 Room: Auditorium INTERACT2, STICH II, CHIMES, IST-3, SPS3, next day PC-Trial, RESPECT, ALIAS, PHANTOM-S, ICSS, EVA-3S, STICH II.
lamp

and the winner is…. I extrapolated 220.000 € to Spanish projects while                                100.000 to Italy, Romania, Belg…

Paris, France and Ingelheim, Germany, 29th August 2011 – Last night at an award ceremony in Paris, the 32 winning projects of the global disease awareness initiative 1 Mission 1 Million – Getting to the Heart of Stroke were announced. The projects were chosen by the public and a panel of experts. They will be awarded a share of the €1 million donation to fulfil the overall mission of preventing as many as one million atrial fibrillation (AF)-related strokes through awareness campaigns. 1 Mission 1 Million is supported by over 45 third-party organisations around the world and is sponsored by Boehringer Ingelheim.

The famous saxofonit of the E Street Band Clarence Clemons suffered a stroke. As far as we know suffered of a brain hemorrhage a underwent surgery twice before death was declared saturday night. Few weeks ago the popular Italian journalist Lamberto Sposini suffered a major hemorrhagic stroke. Delays in the emergency transport system (as in Rome) and prevention strategies (as in Miami) may be further optimized as widely discussed. While VIP are involved, the mass media interest may trigger the attention of the population on the topic.

 

A large study called EPICOR reported ….All patterns were significantly inversely associated with ischemic stroke except the Greek Index, with the strongest association for the Italian Index [HR = 0.37 (95%CI = 0.19-0.70) … suggesting how the adherence to the dietary regimen may protect from stroke

see on J Nutr. 2011 May 31.

The 1 mission 1 million site report that soon the on line voting will be open ….

Sorry, the deadline for application was 31st december 2010. All submitted projects are now being reviewed by our expert panel.
Vote online for your favourite ideas from mid-February 2011
Tell friends and family to visit the campaign website

From Louisiana a new survey on dabigatran published on circulation in january : Dabigatran is a reasonable alternative to warfarin in patients requiring cardioversion.

From Manchester (UK) a meta-analysis reporting how dabigatran may be more effective than aspirin/placebo  in reducing risk of stroke, systemic embolization and mortality in AF… see on Thrombosis anf Haemostasis Oct issue

As reported by a recent paper on Stroke MAs with atrial fibrillation have a higher stroke recurrence risk and more severe recurrences than do NHWs but no difference in all-cause mortality. Aggressive stroke prevention measures focused on MAs are warranted.

Stroke is the second leading cause of death for people above the age of 60, and the fifth leading cause in people aged 15 to 59. Stroke also attacks children, including newborns.  Each year, nearly six million people die from stroke. In fact, stroke is responsible for more deaths every year than those attributed to AIDS, tuberculosis and malaria put together – three diseases which have set the benchmark for successful public health advocacy, capturing the attention of the world’s media and which consequently has provoked world leaders, governments and many sectors of civil society to act. by WSO

on 30 August 2010

Ingelheim, Germany – Report: The European Society of Cardiology (ESC) today issued a revised version of  guidelines for the management of atrial fibrillation (AF), including guidance on the role of thge new oral treatment, dabigatran etexilate, for the prevention of embolism in patients with atrial fibrillation (AF).

At the same time, Boehringer Ingelheim confirms that Food and Drug Administration (FDA) granted a priority review designation for Boehringer Ingelheim’s novel oral direct thrombin inhibitor (DTI) dabigatran etexilate for the prevention of stroke in AF. A priority review designation is given to new drugs that are expected to offer large advances in treatment, or provide a treatment where no adequate therapy exists. An FDA advisory committee will meet on Monday, September 20th, to review and discuss dabigatran etexilate data.

In addition to the US, the registration process for dabigatran etexilate is underway in EU, Japan and other countries. The company expects to receive a marketing authorization for dabigatran etexilate in first countries by end of 2010 or beginning of 2011. The drug availability was expected according to many opinions in fall winter 2010. Similar molecules are expected also by other companies. For people with AF, it is the first competitor to warfarin that is likely to be marketed for stroke prevention, although caution is still urged by reviewers. Stay tuned….